Frontiers in Cardiovascular Medicine
MARCH 12, 2024
Cardiogenic shock (CS) is a time-sensitive and hemodynamically complex syndrome with a broad spectrum of etiologies and clinical presentations. Despite contemporary therapies, CS continues to maintain high morbidity and mortality ranging from 35 to 50%.
Journal of the American Heart Association
MARCH 8, 2024
Cardiogenic shock continues to carry a high mortality rate despite contemporary care, with no breakthrough therapies shown to improve survival over the past few decades. A slowly maturing evidence base has suggested that cardiogenic shock teams may improve patient outcomes.
Journal of the American Heart Association
FEBRUARY 23, 2024
BackgroundThe effects of pharmacological therapy on cardiogenic shock (CS) survivors have not been extensively studied. Journal of the American Heart Association, Ahead of Print.
DAIC
FEBRUARY 29, 2024
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
Dr. Smith's ECG Blog
NOVEMBER 19, 2016
Authors' commentary: Cardiogenic shock in the setting of severe aortic stenosis. This patient’s severe aortic stenosis (AS) and associated severe cardiogenic shock likely created the ECG pattern, resulting in a very difficult challenge for our inpatient team. If you can use Doppler, then you can diagnose it.
Dr. Smith's ECG Blog
NOVEMBER 26, 2018
The axiom of "type 1 (ACS, plaque rupture) STEMIs are not tachycardic unless they are in cardiogenic shock" is not applicable outside of sinus rhythm. We discussed several pharmacologic and electrical options. We first gave adenosine 6mg.
Expert insights. Personalized for you.
145 
Let's personalize your content